MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.04
+0.17
+3.49%
Closed 16:00 04/08 EDT
OPEN
4.860
PREV CLOSE
4.870
HIGH
5.25
LOW
4.850
VOLUME
77.06K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
2.250
MARKET CAP
23.32M
P/E (TTM)
-2.1916
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EYEG stock price target is 90.00 with a high estimate of 90.00 and a low estimate of 90.00.

EPS

EYEG News

More
  • Company News for Apr 1, 2020
  • Zacks · 04/01 14:04
  • Mid-Afternoon Market Update: Dow Falls Over 100 Points; Amarin Shares Slide
  • Benzinga · 03/31 18:36
  • AMRN, PSTV, SRG and PBFX among midday movers
  • Seeking Alpha - Article · 03/31 16:41
  • Mid-Day Market Update: SG Blocks Surges Following Q4 Results; Seanergy Maritime Shares Plummet
  • Benzinga · 03/31 16:03

Industry

Pharmaceuticals
+2.77%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About EYEG

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
More

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.